Nextar is pleased to announce positive pre-clinical acute toxicity results for our proprietary BTLS delivery technology, which facilitates targeted delivery of versatile drugs into the brain. These results present a significant milestone in the clinical development of our pipeline of proprietary novel brain therapies. Furthermore, these results add substantial value to Nextar's ability to commercialize and partner with other pharmaceutical companies looking to develop brain and CNS targeted therapeutics.
Nextar's proprietary BTLS drug-delivery platform is a liposomal vehicle combined with a unique Targeter that allows molecules to cross the Blood-Brain Barrier, thus enabling brain-specific delivery of versatile therapeutic agents. Read more about our platform's advantages
.